June 17, 2019 – The Trump administration’s final rule mandating that drug companies include the wholesale acquisition cost (WAC) in direct-to-consumer (DTC) television ads for many drugs “exceeds [the Department of Health and Human Services’ (HHS’)] statutory authority, violates the First Amendment, and should therefore be set aside,” according to a lawsuit filed Friday, less […]
Read more
May 23, 2019 – Concern over drug pricing remains a healthcare policy issue that enjoys bipartisan support and will remain on the table for the Trump administration and Congress as campaigns for the 2020 election ramp up, according to Kate Rawson, senior editor at Prevision Policy. Speaking at a session of the Coalition for Healthcare […]
Read more
April 8, 2019 – The first television ads including drug price information are hitting the airwaves, reinforcing the point that list price is a highly misleading metric, and Pharmaceutical Research and Manufacturers of America (PhRMA) members are preparing to voluntarily refer consumers to online drug pricing information in their drug ads within a few weeks. […]
Read more
Jan. 15, 2019 – In comments to the Centers for Medicare and Medicaid Services (CMS) regarding its proposal to require that drug companies include the wholesale acquisition cost (WAC) of a drug in direct-to-consumer (DTC) television ads, industry trade groups and pharmaceutical companies largely are in agreement that doing so would confuse consumers, that CMS […]
Read more
Dec. 17, 2018 – The Coalition for Healthcare Communication (CHC) finds the recent proposal to require drug list prices in direct-to-consumer (DTC) television ads “detrimental to the interests of both health providers and patients,” and raises numerous practical and legal concerns to support that position in its official comment filed Dec. 14 with the Centers […]
Read more
Dec. 10, 2018 – The Health and Human Services (HHS) proposal to require that drug companies include drug list prices in direct-to-consumer (DTC) ads could potentially confuse patients, and it also could cause patients to defer treatment because of the misleading price tag, according to Robert Zirkelbach, EVP of public affairs, Pharmaceutical Research and Manufacturers […]
Read more
Nov. 30, 2018 – The 2018 midterm elections resulted in a divided Congress, questions about possible agency changes, and uncertainty related to drug pricing policy and the Affordable Care Act, according to Kate Rawson, senior editor, Prevision Policy and The RPM Report, who spoke at the Coalition for Healthcare Communication’s “2018 Post-election Conference on Healthcare […]
Read more
Nov. 28, 2018 — When it comes to healthcare in the United States, “we’ve got a lot of work to do in promoting transparency, bringing down cost, and making sure we are tying reimbursement to value of care rather than quantity of care,” Sen. Chris Coons (D-Del.) told attendees of the Coalition for Healthcare Communication’s […]
Read more
Sept. 24, 2018 — With the amendment to fund the implementation of mandatory drug prices in consumer advertising stripped out of the spending bill to which it had been attached, the question of whether or how quickly this drug pricing mandate will move forward remains unclear. The amendment, from Sens. Dick Durbin (D-Ill.) and Charles […]
Read more Aug. 24, 2018 – Yesterday was a one-two punch in the Trump administration’s effort to move forward a plan to require that drug manufacturers include drug prices in ads directed toward consumers, as the White House Office of Management and Budget (OMB) reviews a proposed rule from the Department of Health & Human Services (HHS) […]
Read more